Skip Nav Destination
About the Journal
Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to epidemiologic studies. The journal also publishes News and Research Watch sections.Read More About the Journal
Impact Factor
39.397
Featured Articles
Hallmarks of Cancer: New Dimensions
Douglas Hanahan
PD-1 blockade in solid tumors with defects in polymerase epsilon
Benoit Rousseau, et al.
Noted This Week
In the phase I ANTLER trial, Caribou Biosciences’ chimeric antigen receptor (CAR) T-cell therapy, CB-010, demonstrated an overall response rate (ORR) of 100% in all five evaluable patients with relapsed/refractory B-cell non-Hodgkin lymphoma; patients had already received a median of three treatments. In addition, 80% experienced a complete response (CR) lasting up to 6 months; three patients developed grade 3 or 4 adverse events within 28 days of treatment. Caribou says that "CB-010 is the first allogeneic anti-CD19 CAR T-cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to limit premature CAR T-cell exhaustion."
Trending - Altmetric
Synthetic Essentiality of Tryptophan 2,3-dioxygenase 2 in APC-Mutated Colorectal Cancer
Last mentioned on Thursday May 19 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer
Last mentioned on Thursday May 19 2022
Gender Equity in Science and Medicine: Breaking the Impasse
Last mentioned on Tuesday May 17 2022
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Last mentioned on Wednesday May 18 2022
Advertisement